Antibody–drug conjugates: Pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned.

Volume: 57, Issue: 6, Pages: 687 - 703
Published: Jun 1, 2018
Abstract
Antibody–drug conjugates are an emerging class of biopharmaceuticals changing the landscape of targeted chemotherapy. These conjugates combine the target specificity of monoclonal antibodies with the anti-cancer activity of small-molecule therapeutics. Several antibody–drug conjugates have received approval for the treatment of various types of cancer including gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), trastuzumab...
Paper Details
Title
Antibody–drug conjugates: Pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned.
Published Date
Jun 1, 2018
Volume
57
Issue
6
Pages
687 - 703
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.